Int. J. Environ. Res. Public Health 2019, 16, 63; doi:10.3390/ijerph16010063 https://www.mdpi.com/1660-4601/16/1/63
Reply to Comment on Dhiman, R. et al. Correlation of Non-Polio Acute Flaccid Paralysis Rate with Pulse Polio Frequency in India. Int. J. Environ. Res. Public Health 2018, 15, 1755
Rachana Dhiman 1, Sandeep C. Prakash 1, V. Sreenivas 2 and Jacob Puliyel 1,* 1 Department of Pediatrics, St Stephens Hospital, Delhi 110054, India; firstname.lastname@example.org (R.D.); email@example.com (S.C.P.) 2 Department of Biostatistics, All India Institute of Medical Sciences, New Delhi 10029, India; firstname.lastname@example.org * Correspondence: email@example.com; Tel.: +91-986-803-5091 Received: 12 December 2018; Accepted: 13 December 2018; Published: 27 December 2018
We thank the authors for their interest in our paper . However, without providing any data or references to support their contentions, they have speculated on eight reasons why the inferences made in our publication are questionable. It appears that none of these objections are valid and we discuss each point in detail below.
1. The correspondent/s draws attention to the fact that pulse polio campaigns target children under ﬁve, whereas AFP surveillance includes all children under 15. They suggest that AFP in children aged 5 to 15 may have inﬂuenced our results wrongly. We disagree that it is wrong to look at AFP surveillance data under 15. First, the correspondent is mistaken in assuming that the inﬂuence of the vaccine will end abruptly at ﬁve years of age and cannot inﬂuence AFP at six years of age just because OPV is given to children under ﬁve. Furthermore, it must be rememberedthatOPVisalive-virusvaccine. Itisknownthatthevaccinevirus,whichisexcreted insewage,cancontaminatethewatersupplyandinducebothprotectioninunvaccinatedchildren and can revert to a virulent form and cause vaccine-virus associated polio paralysis . In this way, pulse polio in children under ﬁve could well inﬂuence AFP in children aged 5–15 years, and therefore, it is appropriate to include them in our evaluation. The incidence of polio in the age group 5–15 years is very low which is the rationale for limiting the vaccination to children under ﬁve years of age. In fact, the incidence of Guillain-Barré syndrome (GBS), which is ordinarily one of the main causes of non-polio AFP (NP AFP), is also much higher in children under four years. The annualized rate for GBS was 1.3/100,000 for children under four years when compared to 0.1/100,000 in the age group of 5 to 15 in the study by Winner and Evans . The inclusion of the AFP rate in children 5–15 years (where the natural incidence is low) will result in the underestimation of the problem we highlighted in our paper, and the AFP rates would have been even higher if we considered only children under ﬁve. 2. The correspondent suggests that a broadened case deﬁnition and the reduced support in human resourcesfromtheWHO,withfewervisitsbytheseofﬁcerstothereportingcenters,maycorrelate to non-polio AFP rates in recent years. The correspondent has provided no data to substantiate this assertion. The broadening of the case deﬁnition took place long before the fall in AFP rate seen from 2011, moreover, a broadened deﬁnition would have resulted in an increase in the reported incidence and cannot explain why AFP rates have fallen steadily since 2011.
Int. J. Environ. Res. Public Health 2019, 16, 63; doi:10.3390/ijerph16010063 www.mdpi.com/journal/ijerph
Int. J. Environ. Res. Public Health 2019, 16, 63 2 of 3
ThesuggestionthatthereportingofAFPhasfallenbecausethenumberofvisitsbyWHOexperts has been scaled down is both unwarranted and mischievous. The AFP surveillance machinery in the country has been set up for meticulous reporting at great recurring cost to the Government of India. AFP cases are investigated within 48 h, which is an AFP surveillance performance indicator. All of the performance indicators from India have consistently been exemplary. It is unfortunate that the correspondents have resorted to innuendo without showing any evidence of a drop in performance from 2011 onwards. 3. The variation seen in the AFP rates in places receiving the same number of pulse polio doses was questioned. Area wise variations in susceptibility to vaccine preventable disease as well as the adverse effects of immunization are well known. In a study of another oral vaccine, the rotavirus vaccine, the incidence of intussusceptions was 27.7/100,000 child-years in Delhi, but was 20 times higher in Vellore, South India (581/100,000 child-years) . 4. It was pointed out that routine immunization coverage improved after 2013–2014, which was not taken into account in our calculations. We did not include routine immunization in our calculations. Routine immunization consists of three doses in the ﬁrst year, one dose in the second year, and one dose in the ﬁfth year. We considered this as a constant in all children. Having assumed full coverage from the start, we looked at the additional pulse polio doses given. As such improvements in coverage were not taken into account, they are unlikely to have signiﬁcantly inﬂuenced the results. 5. It was suggested that we had not considered the global switch in 2016 from tOPV to bOPV. It was also stated that we had not considered the low coverage with IPV due to global shortages in our calculations. How this switch to bOPV that was to happen in 2016 could inﬂuence a fall in the AFP rate ﬁve years earlier in 2011, has not been explained by the correspondent. With regard to shortages in IPV, it must be clariﬁed that IPV has been used very infrequently in India and so the shortages of IPV did not have any signiﬁcant impact. Our calculations only considered the doses of oral vaccine given, which was not inﬂuenced by the IPV shortage. 6. The correspondent writes that the incidence of post vaccination paralysis in the literature is about one in 2–3 million doses, and that it was seen in those given the vaccine for the ﬁrst time. Therefore, they say that there is no biological plausibility for the conclusion on correlation as described by us. This appears to be a straw man argument. We did not say that the NP AFP reported in our paper were cases of vaccine induced paralysis. Non-polio AFP, by its very deﬁnition, excludes polio vaccine induced paralysis. 7. The correspondent claims that non-polio entroviruses (NPEV) causing polio like paralysis was unaccounted for in our paper. This is not correct. It seems that the correspondent has not read our paper carefully. I quote from the paper: “We speculate that repeated doses of live vaccine virus delivered to the intestine may colonize the gut and alter the viral microbiome of the intestine, and this can result in strain shifts of enteropathogens. It is possible that new neurotropic enteroviruses colonizing the gut may induce paralysis”. 8. The correspondent suggests that in India, we do not use the classical AFP criteria practiced in Western countries, but have used NP AFP rates from the West when making our comparisons. We clarify that we have used the WHO recommended surveillance standards, not a ‘Western standard’. This was quoted as Reference  in our paper.
It would appear that the correspondent is clutching at straws to discredit our ﬁndings. We hope we have clariﬁed all of their queries.
Int. J. Environ. Res. Public Health 2019, 16, 63 3 of 3
Conﬂicts of Interest: The authors declare no conﬂicts of interest.
References 1. Dhiman, R.; Prakash, S.C.; Sreenivas, V.; Puliyel, J. Correlation between Non-Polio Acute Flaccid Paralysis Rates with Pulse Polio Frequency in India. Int. J. Environ. Res. Public Health 2018, 15, 1755. [CrossRef] [PubMed] 2. WHO GlobalVaccine Safety. Information Sheet ObservedRate ofVaccine Reactions PolioVaccine. May 2014. Available online: https://www.who.int/vaccine_safety/initiative/tools/polio_vaccine_rates_information_ sheet.pdf (accessed on 1 December 2018). 3. Winner, S.J.; Evans, J.G. Age-speciﬁc incidence of Guillain-Barré syndrome in Oxfordshire. Q.J.Med. 1990, 77, 1297–1304. [CrossRef] [PubMed] 4. John, J.; Kawade, A.; Rongsen-Chandola, T.; Bavdekar, A.; Bhandari, N.; Taneja, S.; Antony, K.; Bhatnagar, V.; Gupta, A.; Kabra, M.; et al. Active surveillance for intussusception in a phase III efﬁcacy trial of an oral monovalent rotavirus vaccine in India. Vaccine 2014, 32 (Suppl. 1), A104–A109. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).